
|Articles|March 17, 2010
Supplements and Featured Publications
- Implications of Early Treatment for Parkinson’s Disease [CME/CPE]
- Volume 16
- Issue 4
Posttest: Implications of Early Treatment for Parkinson's Disease
Advertisement
Instructions
After reading “Implications of Early Treatment for Parkinson’s Disease,” complete the program evaluation and select the 1 best answer to each of the following questions.
A statement of continuing education hours will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher.
Articles in this issue
over 16 years ago
Participating Facultyover 16 years ago
Early Pharmacologic Treatment in Parkinson's DiseaseAdvertisement
Related to this article

At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.

Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.

About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.

A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
4
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
5


